Sibutramine

CHEMBL1419 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

279.8 g/mol

LogP

5.4

Phase

4

Sibutramine is a centrally acting serotonin-norepinephrine reuptake inhibitor originally developed as an antidepressant and later used as an anti-obesity agent for weight management. By inhibiting reuptake of serotonin, norepinephrine, and to a lesser extent dopamine, it promotes satiety and reduces food intake while modestly increasing energy expenditure. It was withdrawn from markets in many countries due to increased risk of major adverse cardiovascular events in high-risk patients.

Moleküler Ağırlık

279,8000 g/mol

LogP

5,40

TPSA

3,20 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Asthma Schizophrenia Bipolar Disorder Obesity Hypertension Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1

InChI

InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3

Molecular Formula

C17H26ClN

HBD / HBA

- / 1

Döndürülebilir Bağlar

5

Ağır Atomlar

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Sibutramine is a centrally acting serotonin-norepinephrine reuptake inhibitor originally developed as an antidepressant and later used as an anti-obesity agent for weight management. By inhibiting reuptake of serotonin, norepinephrine, and to a lesser extent dopamine, it promotes satiety and reduces food intake while modestly increasing energy expenditure. It was withdrawn from markets in many countries due to increased risk of major adverse cardiovascular events in high-risk patients.

Yes, Sibutramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1419. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5210. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Sibutramine PillFYI'da

Yapı

Hızlı Veriler

Formül: C17H26ClN

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.